DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Trial Profile

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Phase of Trial: Phase II

Latest Information Update: 19 Jan 2018

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Adenocarcinoma; Adrenocortical carcinoma; Cholangiocarcinoma; Choriocarcinoma; Endometrial cancer; Fallopian tube cancer; Germ cell and embryonal neoplasms; Neuroendocrine tumours; Ovarian cancer; Seminoma; Squamous cell cancer; Teratoma
  • Focus Therapeutic Use
  • Acronyms DART
  • Most Recent Events

    • 16 Nov 2017 Planned number of patients changed from 334 to 707.
    • 18 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 27 Jul 2016 Planned initiation date changed from 1 Jun 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top